SBIR Phase II: Scalable Synthesis and Processing of Nanocrystalline Hydroxyapatite

SBIR 第二阶段：纳米晶羟基磷灰石的可规模化合成和加工

• 批准号: 0349884
• 负责人: Edward Ahn
• 金额: $ 50万
• 依托单位: Angstrom Medica, Incorporated
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-02-15 至 2008-01-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0349884&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Scalable; Synthesis

0349884AhnThis Small Business Innovation Research Phase II Project proposes to use a newly developed synthetic nanocrystalline hydroxyapatite (HAP) bone material to produce high-strength, resorbable synthetic bone implants for anterior cruciate ligament surgeries. This material solves the problem of current orthopedic implants (made of polymer and/or metal) which either permanently reside as foreign material in the body or quickly degrade into a formless mass of non-ossified, non-load bearing tissue. The objectives of the Phase II work are to concurrently scale up manufacturing processes for HAP to near-commercial levels while developing an anterior cruciate ligament (ACL) prototype product for testing in vivo.The commercial impact of this project will be in the area of orthopedics. The proposed technology will help decrease the time of healing in surgeries requiring implants (fractiures, ACL) and will minimize the need for second surgeries to remove the screws and/or to correct for morbidities.

0349884An这个小型企业创新研究第二阶段项目建议使用一种新开发的合成纳米晶羟基磷灰石(HAP)骨材料来生产高强度、可吸收的合成骨植入物，用于前十字韧带手术。这种材料解决了目前骨科植入物(由聚合物和/或金属制成)的问题，这些植入物要么作为异物永久驻留在体内，要么迅速降解成无形态的非骨化、非承重组织块。第二阶段工作的目标是同时将HAP的制造工艺扩大到接近商业水平，同时开发用于活体测试的前十字韧带(ACL)原型产品。该项目将在整形外科领域产生商业影响。这项拟议的技术将有助于减少需要植入(部分，前交叉韧带)的手术的愈合时间，并将最大限度地减少第二次手术移除螺钉和/或纠正疾病的需要。